Hyperion DeFi (HYPD) Competitors $7.20 +0.51 (+7.62%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HYPD vs. TVGN, ACTU, GLSI, ELDN, RAPT, CRBU, CRDF, ACOG, SLS, and BTMDShould you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Semper Paratus Acquisition (TVGN), Actuate Therapeutics (ACTU), Greenwich LifeSciences (GLSI), Eledon Pharmaceuticals (ELDN), Rapt Therapeutics (RAPT), Caribou Biosciences (CRBU), Cardiff Oncology (CRDF), Alpha Cognition (ACOG), SELLAS Life Sciences Group (SLS), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Hyperion DeFi vs. Its Competitors Semper Paratus Acquisition Actuate Therapeutics Greenwich LifeSciences Eledon Pharmaceuticals Rapt Therapeutics Caribou Biosciences Cardiff Oncology Alpha Cognition SELLAS Life Sciences Group biote Tevogen Bio (NASDAQ:TVGN) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment. Do analysts prefer TVGN or HYPD? Tevogen Bio currently has a consensus price target of $10.00, indicating a potential upside of 954.52%. Hyperion DeFi has a consensus price target of $2.00, indicating a potential downside of 72.22%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tevogen Bio is more favorable than Hyperion DeFi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hyperion DeFi 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders believe in TVGN or HYPD? 25.8% of Hyperion DeFi shares are owned by institutional investors. 73.2% of Tevogen Bio shares are owned by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, TVGN or HYPD? Tevogen Bio has higher earnings, but lower revenue than Hyperion DeFi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTevogen BioN/AN/A-$13.73MN/AN/AHyperion DeFi$60K682.80-$49.82M-$58.40-0.12 Which has more risk and volatility, TVGN or HYPD? Tevogen Bio has a beta of -0.77, indicating that its share price is 177% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Does the media favor TVGN or HYPD? In the previous week, Tevogen Bio and Tevogen Bio both had 7 articles in the media. Hyperion DeFi's average media sentiment score of 0.41 beat Tevogen Bio's score of 0.27 indicating that Hyperion DeFi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperion DeFi 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TVGN or HYPD more profitable? Tevogen Bio has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Tevogen Bio's return on equity of 0.00% beat Hyperion DeFi's return on equity.Company Net Margins Return on Equity Return on Assets Tevogen BioN/A N/A -934.56% Hyperion DeFi -62,238.41%-876.25%-181.67% SummaryTevogen Bio beats Hyperion DeFi on 7 of the 12 factors compared between the two stocks. Get Hyperion DeFi News Delivered to You Automatically Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HYPD vs. The Competition Export to ExcelMetricHyperion DeFiBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.10M$138.55M$5.67B$9.83BDividend YieldN/A3.74%3.79%4.08%P/E Ratio-0.123.8230.5825.12Price / Sales682.804,361.81464.55116.64Price / CashN/A13.1937.4059.05Price / Book1.1044.949.096.18Net Income-$49.82M-$90.99M$3.25B$264.89M7 Day Performance-3.49%1.62%4.76%2.66%1 Month Performance-44.14%5.18%6.72%3.05%1 Year Performance-88.54%184.04%30.51%25.05% Hyperion DeFi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HYPDHyperion DeFi0.3669 of 5 stars$7.20+7.6%$2.00-72.2%-89.1%$38.10M$60K-0.1240News CoverageEarnings ReportGap UpTVGNSemper Paratus Acquisition3.7632 of 5 stars$0.98+8.8%$10.00+920.4%+35.2%$165.60MN/A0.003ACTUActuate Therapeutics2.2528 of 5 stars$8.01-0.1%$20.50+155.9%-10.2%$164.17MN/A0.0010News CoverageEarnings ReportGLSIGreenwich LifeSciences1.3864 of 5 stars$12.49+2.5%$39.00+212.2%-7.0%$162.83MN/A-9.913Earnings ReportELDNEledon Pharmaceuticals1.8771 of 5 stars$2.71-0.4%$10.00+269.0%-3.7%$162.58MN/A-1.2910Earnings ReportUpcoming EarningsShort Interest ↑RAPTRapt Therapeutics4.6641 of 5 stars$9.55-2.7%$21.43+124.4%-34.3%$162.24M$1.53M-0.6780Analyst ForecastCRBUCaribou Biosciences3.0111 of 5 stars$1.71-1.2%$6.67+289.9%+5.3%$160.90M$9.99M-1.06100News CoverageEarnings ReportAnalyst RevisionGap UpCRDFCardiff Oncology1.8934 of 5 stars$2.33-2.5%$10.10+333.5%+11.9%$159M$680K-2.6820ACOGAlpha Cognition1.7654 of 5 stars$9.99+0.9%$20.00+100.2%N/A$158.60MN/A-8.32N/ANews CoverageEarnings ReportGap UpSLSSELLAS Life Sciences Group2.8948 of 5 stars$1.54-2.5%$7.00+354.5%+29.2%$157.65M$1M-4.0510Earnings ReportBTMDbiote2.5144 of 5 stars$2.82-2.1%$6.00+112.8%-49.4%$157.57M$197.19M3.13194High Trading Volume Related Companies and Tools Related Companies TVGN Competitors ACTU Competitors GLSI Competitors ELDN Competitors RAPT Competitors CRBU Competitors CRDF Competitors ACOG Competitors SLS Competitors BTMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HYPD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hyperion DeFi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hyperion DeFi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access